ParkinsonFranceV1, Main, Exploration, bibRecord, 000227

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.

Identifieur interne : 000227 ( Main/Exploration ); précédent : 000226; suivant : 000228

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.

Auteurs : Michel Engeln [France] ; Solène Ansquer [France] ; Emilie Dugast [France] ; Erwan Bezard [France] ; David Belin [Royaume-Uni] ; Pierre-Olivier Fernagut [France]

Source :

Neuropharmacology [ 1873-7064 ] ; 2016.

RBID : pubmed:27216859

Abstract

Impulse control disorders (ICDs) are debilitating side effects of dopamine replacement therapy (DRT) in Parkinson's disease (PD) that severely affect the quality of life of patients. While DRT, the pattern and extent of neurodegeneration, and prodromic factors of vulnerability (e.g. impulsivity) have all been hypothesized to play a role in the development of ICDs, their respective, and potentially interacting, contributions remain to be established. High impulsive (HI), Intermediate (Int) or low impulsive (LI) rats were identified based on their performance in both a differential reinforcement of low rate of responding (DRL) and a fixed consecutive number (FCN) schedules, that operationalize two independent facets of impulsivity, waiting and action inhibition (motor impulsivity). We investigated whether high impulsivity trait influenced the progressive development of a parkinsonian state induced by viral-mediated overexpression of α-synuclein, and whether impulsivity trait and nigrostriatal neurodegeneration independently or jointly influenced the effects of DRT on impulse control. α-synuclein-induced nigrostriatal neurodegeneration increased both waiting and motor impulsivity. The D2/D3 dopamine receptor agonist pramipexole exacerbated motor impulsivity more than waiting. However, the pramipexole-induced increase in waiting impulsivity observed in both sham and lesioned rats, was more pronounced in HI lesioned rats, which displayed a restricted α-synuclein-induced dopaminergic neurodegeneration. Thus, a PD-like nigrostriatal lesion increases both motor and waiting impulsivity, but its interaction with a pre-existing impulsivity trait, which, at the cellular level, confers resilience to dopaminergic neurodegeneration, worsens the detrimental effects of D2/D3 dopamine receptor agonists on inhibitory control.

DOI: 10.1016/j.neuropharm.2016.05.013
PubMed: 27216859

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.</title>
<author><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ansquer, Solene" sort="Ansquer, Solene" uniqKey="Ansquer S" first="Solène" last="Ansquer">Solène Ansquer</name>
<affiliation wicri:level="4"><nlm:affiliation>Service de neurologie de l'hôpital de Poitiers, F-86021, Poitiers, France; Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de neurologie de l'hôpital de Poitiers, F-86021, Poitiers, France; Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
<orgName type="university">Université de Poitiers</orgName>
</affiliation>
</author>
<author><name sortKey="Dugast, Emilie" sort="Dugast, Emilie" uniqKey="Dugast E" first="Emilie" last="Dugast">Emilie Dugast</name>
<affiliation wicri:level="4"><nlm:affiliation>Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers, France; INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers, France; INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
<orgName type="university">Université de Poitiers</orgName>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Belin, David" sort="Belin, David" uniqKey="Belin D" first="David" last="Belin">David Belin</name>
<affiliation wicri:level="4"><nlm:affiliation>INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France; Department of Pharmacology, University of Cambridge, CB2 1PD, Cambridge, UK; Behavioural and Clinical Neuroscience Institute of the University of Cambridge, CB2 3ED, Cambridge, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France; Department of Pharmacology, University of Cambridge, CB2 1PD, Cambridge, UK; Behavioural and Clinical Neuroscience Institute of the University of Cambridge, CB2 3ED, Cambridge</wicri:regionArea>
<orgName type="university">Université de Cambridge</orgName>
<placeName><settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France. Electronic address: pierre-olivier.fernagut@u-bordeaux.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27216859</idno>
<idno type="pmid">27216859</idno>
<idno type="doi">10.1016/j.neuropharm.2016.05.013</idno>
<idno type="wicri:Area/PubMed/Corpus">000082</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000082</idno>
<idno type="wicri:Area/PubMed/Curation">000082</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000082</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000082</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000082</idno>
<idno type="wicri:Area/Ncbi/Merge">001A33</idno>
<idno type="wicri:Area/Ncbi/Curation">001A33</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001A33</idno>
<idno type="wicri:Area/Main/Merge">000229</idno>
<idno type="wicri:Area/Main/Curation">000227</idno>
<idno type="wicri:Area/Main/Exploration">000227</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.</title>
<author><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ansquer, Solene" sort="Ansquer, Solene" uniqKey="Ansquer S" first="Solène" last="Ansquer">Solène Ansquer</name>
<affiliation wicri:level="4"><nlm:affiliation>Service de neurologie de l'hôpital de Poitiers, F-86021, Poitiers, France; Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de neurologie de l'hôpital de Poitiers, F-86021, Poitiers, France; Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
<orgName type="university">Université de Poitiers</orgName>
</affiliation>
</author>
<author><name sortKey="Dugast, Emilie" sort="Dugast, Emilie" uniqKey="Dugast E" first="Emilie" last="Dugast">Emilie Dugast</name>
<affiliation wicri:level="4"><nlm:affiliation>Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers, France; INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Poitiers, F-86000, Poitiers, France; CIC INSERM 1402, CHU de Poitiers, Poitiers, France; INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
<orgName type="university">Université de Poitiers</orgName>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Belin, David" sort="Belin, David" uniqKey="Belin D" first="David" last="Belin">David Belin</name>
<affiliation wicri:level="4"><nlm:affiliation>INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France; Department of Pharmacology, University of Cambridge, CB2 1PD, Cambridge, UK; Behavioural and Clinical Neuroscience Institute of the University of Cambridge, CB2 3ED, Cambridge, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France; Department of Pharmacology, University of Cambridge, CB2 1PD, Cambridge, UK; Behavioural and Clinical Neuroscience Institute of the University of Cambridge, CB2 3ED, Cambridge</wicri:regionArea>
<orgName type="university">Université de Cambridge</orgName>
<placeName><settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name>
<affiliation wicri:level="3"><nlm:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France. Electronic address: pierre-olivier.fernagut@u-bordeaux.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Neuropharmacology</title>
<idno type="eISSN">1873-7064</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Impulse control disorders (ICDs) are debilitating side effects of dopamine replacement therapy (DRT) in Parkinson's disease (PD) that severely affect the quality of life of patients. While DRT, the pattern and extent of neurodegeneration, and prodromic factors of vulnerability (e.g. impulsivity) have all been hypothesized to play a role in the development of ICDs, their respective, and potentially interacting, contributions remain to be established. High impulsive (HI), Intermediate (Int) or low impulsive (LI) rats were identified based on their performance in both a differential reinforcement of low rate of responding (DRL) and a fixed consecutive number (FCN) schedules, that operationalize two independent facets of impulsivity, waiting and action inhibition (motor impulsivity). We investigated whether high impulsivity trait influenced the progressive development of a parkinsonian state induced by viral-mediated overexpression of α-synuclein, and whether impulsivity trait and nigrostriatal neurodegeneration independently or jointly influenced the effects of DRT on impulse control. α-synuclein-induced nigrostriatal neurodegeneration increased both waiting and motor impulsivity. The D2/D3 dopamine receptor agonist pramipexole exacerbated motor impulsivity more than waiting. However, the pramipexole-induced increase in waiting impulsivity observed in both sham and lesioned rats, was more pronounced in HI lesioned rats, which displayed a restricted α-synuclein-induced dopaminergic neurodegeneration. Thus, a PD-like nigrostriatal lesion increases both motor and waiting impulsivity, but its interaction with a pre-existing impulsivity trait, which, at the cellular level, confers resilience to dopaminergic neurodegeneration, worsens the detrimental effects of D2/D3 dopamine receptor agonists on inhibitory control.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Angleterre de l'Est</li>
<li>Aquitaine</li>
<li>Nouvelle-Aquitaine</li>
<li>Poitou-Charentes</li>
</region>
<settlement><li>Bordeaux</li>
<li>Cambridge</li>
<li>Poitiers</li>
</settlement>
<orgName><li>Université de Cambridge</li>
<li>Université de Poitiers</li>
</orgName>
</list>
<tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name>
</region>
<name sortKey="Ansquer, Solene" sort="Ansquer, Solene" uniqKey="Ansquer S" first="Solène" last="Ansquer">Solène Ansquer</name>
<name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<name sortKey="Dugast, Emilie" sort="Dugast, Emilie" uniqKey="Dugast E" first="Emilie" last="Dugast">Emilie Dugast</name>
<name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Belin, David" sort="Belin, David" uniqKey="Belin D" first="David" last="Belin">David Belin</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000227 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000227 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27216859
   |texte=   Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27216859" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.